News Room

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

| Chembio | No Comments
HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an…
NACCHO Webinar Image

Preparing for the 2021-2022 Flu Season: What to Expect, and How to Plan Webinar

| Chembio | No Comments
Status™ COVID-19/FLU Product COVID-19 has shown us that early detection and response is essential to curbing the spread of infectious diseases. Experts say the 2021-2022 Flu and Respiratory season will…

Watch the recorded Webinar, Fighting the Syphilis & HIV Epidemics: Voices from the Field

| Chembio | No Comments
Date: May 27th, 2021Time: 2:30pm-3:45pm ESTHost: National Coalition of STD Directors   Description The National Coalition of STD Directors, in partnership with Chembio, is excited to present an informational webinar…
Status COVID-19 Flu Background Image, Nurse and Patients

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

| Chembio | No Comments
Apr 1, 2021: In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes Chembio Diagnostics, Inc. (Nasdaq: CEMI),…
David W. Bespalko

Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors

| Chembio | No Comments
Mar 8, 2021 HAUPPAUGE, N.Y., (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to the Company’s Board of Directors,…

Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems

| Chembio | No Comments
Jan 14, 2021 Enters Exclusive U.K. and Ireland Distribution Agreement with Luas Diagnostics HAUPPAUGE, N.Y., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases,…

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors

| Chembio | No Comments
HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company’s Board of Directors.…
DPP SARS-CoV-2 Antigen System

Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System

| Chembio | No Comments
HAUPPAUGE, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and…

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

| Chembio | No Comments
Nov 13, 2020 HAUPPAUGE, N.Y. (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received…